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Inherited platelet disorders are a rare, but probably underdiagnosed, cause of symptomatic bleeding. They are characterized by abnormalities of
platelet number (inherited thrombocytopenias), function (inherited disorders of platelet function) or both. This review briefly discusses the
inherited platelet disorders with respect to molecular defects, diagnostic evaluation and treatment strategies.
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The inherited platelet disorders are a heterogeneous group
of rare diseases including quantitative and/or qualitative platelet
defects. They present as primary hemostatic defects character-
ized by easy bruising, epistaxis, menorrhagia, and excessive
bleeding from trauma and dental or surgical interventions [1].
While the recent advances in the understanding of the platelet
molecular biology have greatly contributed to the elucidation of
the pathogenic mechanisms underlying these inherited bleeding
conditions, their heterogeneity poses diagnostic challenges as
the tests needed to evaluate platelet disorders are often restricted
to specialized coagulation laboratory centers [2,3].
The main clinical, diagnostic and therapeutic aspects of inher-
ited platelet disorders will be discussed in this review. Table 1
summarizes the classification of inherited platelet disorders.
2. Disorders of platelet number
2.1. MYH9-related platelet disorders
MYH9-related disorders indicate a group of autosomal
dominant macrothrombocytopenias that include May-Hegglin
anomaly, Sebastian, Fechtner and Epstein syndromes [4]. This
disorder is caused by mutations within MYH9, the gene that
encodes non-muscle myosin IIA heavy chain (NMMHC-IIA)
[5]. The NMMHC-IIA is part of the non-muscle myosin IIA
hexamer that is a component of the contractile cytoskeleton in
megakaryocytes, platelets and neutrophils. MYH9 mutations
associated with MYH9-related disorder are predicted to disrupt
stability of the non-muscle myosin IIA hexamer or to disrupt its
interaction with other regulatory proteins [6]. Thrombocytope-
nia derives from ineffective thrombopoiesis. The clinical
features of MYH9-related disorders include mild bleeding
diathesis, sensorineural hearing loss, glomerulonephritis and
cataract. The association of macrothrombocytopenia (platelet
count is usually in the range of 20–130×109/l) and one or more
of the recognized clinical associations ofMYH9-related disorder
is highly suggestive of this diagnosis. In addition to macro-
thrombocytopenia, neutrophil inclusions (Döhle-like bodies on
May-Grünwald–Giemsa stained peripheral blood smears)
recognized by monoclonal antibodies against NMMHC-IIA
are a constant feature of this disorder [7]. However, the
definitive diagnosis requires the demonstration of a causative
mutation within MYH9. The management of bleeding include
the administration of antifibrinolytic agents (epsilon aminoca-proic acid or tranexamic acid) or transfusion of platelets for
serious bleeding or as prophylaxis prior to major surgery when
platelet count is particularly low.
2.2. Congenital amegakaryocytic thrombocytopenia
Congenital amegakaryocytic thrombocytopenia is an autoso-
mal recessive disorder characterized by neonatal isolated hypo-
megakaryocytic thrombocytopenia that develops into a severe
aplastic anemia in later childhood. It is caused by mutations in the
c-MPL gene with consequent deficiency in expression or function
of the thrombopoietin receptor [8]. Treatment includes platelet
transfusions and hemopoietic stem cell transplantation (HSCT)
when bone marrow failure develops.
2.3. Thrombocytopenia associated with skeletal defects
This group of platelet disorders includes amegakaryo-
cytic thrombocytopenia with radio-ulnar synostosis, thrombocy-
topenia with absent radii (TAR) and velocardiofacial syndrome.
Amegakaryocytic thrombocytopenia with radio-ulnar synosto-
sis is an autosomal dominant disorder characterized by congenital
amegakaryocytic thrombocytopenia, aplastic anemia, proximal
radial ulnar synostosis, clinodactyly, syndactyly, hip dysplasia and
sensorineural hearing loss [9]. Molecular analysis has demon-
strated the presence of mutations in the HOXA11 gene. The
HOXA11 gene belongs to the family of homeobox genes, which
encode regulatory proteins that are central to bone morphology as
well as hematopoietic differentiation and proliferation [10].
Thrombocytopenia with absent radii is an autosomal re-
cessive disease characterized by hypomegakaryocytic throm-
bocytopenia and bilateral radial aplasia. However, relevant
heterogeneity regarding additional congenital malformations
and clinical evolution has been documented. Thrombocytopenia
is severe at birth, but platelet number increases with age.
Platelets and megakaryocytes of TAR patients are refractory to
thrombopoietin and the functional defect has been suggested to
be associated with a decrease in c-MPL transcripts and con-
sequent defective thrombopoietin signaling pathway [11].
DiGeorge/Velocardiofacial syndrome is an autosomal dom-
inant disorder associated with hemizigous microdeletions in
GPIBB gene and characterized by macrothrombocytopenia,
cleft palate, cardiac abnormalities, typical facies and mental
retardation [12]. Since the deletions include GPIBB, one of the
three genes defective in Bernard-Soulier syndrome (BSS),
patients with DiGeorge/Velocardiofacial syndrome are also
Table 1
Classification of inherited platelet disorders
Inheritance gene (chromosome) Laboratory and clinical characteristics Therapy
Disorders of platelet number
1)MYH9-related platelet
disorders a
AD MYH9 (22q12-13) Macrothrombocytopenia, neutrophil inclusions, mild





















Platelet transfusion radial aplasia
—DiGeorge/Velocardiofacial
syndrome
AD GPIBB (22q11) Macrothrombocytopenia, cleft palate,




X-linked GATA1 (Xp11.23) Macrothrombocytopenia, dyserythropoietic anemia Platelet transfusion, HSCT
5) Thrombocytopenia with
predisposition to leukemia
AD CBFA2 (21q22) Aspirin-like functional platelet defect,
evolution in AML
DDAVP, platelet transfusion
6) Montreal platelet syndrome AD Unknown Macrothrombocytopenia with spontaneous platelet





AD GPIBA (some cases) Macrothrombocytopenia, normal platelet function Antifibrinolytic agents, DDAVP
Disorders of platelet function
1) Platelet-type VWD AD GPIBA (17p13) Spontaneous platelet aggregation,






Normal platelet count and morphology,
prolonged BT and
PFA.-100, RIPA present, no aggregation to agonists
Antifibrinolytic agents, platelet
transfusion, rFVIIa, HSCT
3) Bernard-Soulier syndrome AR GIBA (17p13),
GIBB (22q11)
GPIX (3q21)
Macrothrombocytopenia, RIPA absent, prolonged




4) Wiskott-Aldrich syndrome X-linked WAS Microthrombocytopenia, immunodeficiency, eczema Platelet transfusion,
splenectomy, HSCT
Disorders of agonist platelet
receptors and
signal transduction
1) TXA2 receptor deficiency AD TBXA2R Impaired aggregation to thromboxane analogues Antifibrinolytic agents, DDAVP
2) ADP receptor deficiency AR P2Y12 Impaired aggregation to ADP Antifibrinolytic agents, DDAVP
Disorders of platelet granules
1) δ-storage pool disease
—Idiopathic δ-storage
pool disease





AR LYST (1q42.1-42.2) Oculocutaneous albinism, peroxidase-positive





AR HPS1, AP3B1, HPS3,
HPS4 HPS5, HPS6,
DTNBP1, HPS8
Oculocutaenous albinism, mild bleeding diathesis,
ceroid-lipofuscin-like lysosomal storage disease
Antifibrinolytic agents, DDAVP
2) α-storage pool disease





AD FLI1 (11q23) Thrombocytopenia, dysmegakaryocytopoiesis,
mental retardation, facial and cardiac
abnormalities, giant α-granules
Antifibrinolytic agents, DDAVP




1) Scott syndrome AR ABCA1 Moderate to severe bleeding, impaired
thrombin generation on activated platelets
Antifibrinolytic agents,
platelet transfusion
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; HSCT, hemopoietic stem cell transplantation; XL, X-linked; AML, acute myeloid leukemia;
DDAVP, desmopressin; VWD, von Willebrand disease; VWF, von Willebrand factor; RIPA, ristocetin-induced platelet aggregation; HMW, high molecular weight;
rFVIIa, recombinant activated factor VII; BT, bleeding time; TXA2, thromboxane A2; ADP, adenosine diphosphate; FV, factor V.
a MYH9-related disorders include entities previously classified as May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, Epstein syndrome.
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function [1]. Bleeding symptoms are absent or mild.
The management of thrombocytopenic disorders associated
with skeletal defects include platelet transfusions and HSCT in
selected cases (see Table 1).
2.4. X-linked thrombocytopenia with dyserythropoiesis
It is an X-linked disorder in which a severe thrombocytopenia is
associated with dyserythropoiesis. Large platelets and red cell
anisopoikilocytosis in peripheral blood and dyserythropoiesis with
abnormal megakaryocytes in the bone marrow are characteristic
findings of this disease. It is due to mutations in the GATA1 gene
which encodes the erythroid and megakaryocyte transcription
factor GATA1 [13]. The management of this disorder include
platelet transfusion and HSCT.
2.5. Thrombocytopenia with predisposition to leukemia
This is an autosomal dominant disorder characterized by
thrombocytopenia and prolonged bleeding time, an aspirin-like
functional platelet defect and a predisposition to develop acute
myeloid leukemia. The condition is linked to mutations or
intragenic deletions in one allele of the CBFA2 gene [14].
2.6. Montreal platelet syndrome
Montreal platelet syndrome is an autosomal dominant macro-
thrombocytopenia characterized by spontaneous in vitro platelet
aggregation in anticoagulated whole blood, platelet-rich plasma
and buffer solutions without calcium and fibrinogen. A partial
defect of calcium-activated neutral protease (calpain) has been
identified in patients with this syndrome. This enzyme is involved
in the cleavage of the cytoskeleton proteins, suggesting that its
deficiency may interfere with the expression of platelet binding
sites for adhesive proteins. Platelet count is severely reduced (5–
40×109/l) and bleeding time usually markedly prolonged [15].
2.7. Mediterranean macrothrombocytopenia
Mediterranean macrothrombocytopenia, described in Greek
and Italian populations, is an autosomal dominant platelet disorder
characterized by varying degrees of thrombocytopenia and the
presence of large platelets in peripheral bloodwith a normal in vitro
platelet function. Although many patients with these features have
recognized to be heterozygous carriers of Bernard-Soulier
syndrome, the molecular etiology of the remaining cases is yet
unexplained [16]. Patients with Mediterranean macrothrombocy-
topenia are asymptomatic or have a mild bleeding diathesis.
3. Disorders of platelet function
3.1. Platelet-type von Willebrand disease
Platelet-type von Willebrand disease (PT-VWD), or pseudo-
VWD, is a rare autosomal dominant bleeding disorder character-
ized by an abnormally enhanced binding of normal vonWillebrandfactor (VWF) by the abnormal platelet membrane glycoprotein
(GP) Ibα receptor [17].
Platelet-type VWD is caused by mutations in the GPIBA gene
located on chromosome 17. To date, only fourmutations have been
reported. Three of these, Gly233Val, Met239Val and Gly233Ser,
are missense mutations and are located within the C-terminal
disulfide loop of the 45-kDa domain of GPIbα [18]. The fourth
mutation, a 27 base pair deletion in the macroglycopeptide-coding
region of the GPIBA gene, has been reported more recently [19].
The result of these mutations is a gain of the functional phenotype
of the platelet membrane GPIbα complex, which has an increased
avidity for VWF, leading to the binding of the largest (high
molecular weight, HMW) VWF multimers to the platelets and to
their clearance from the circulation with the resulting thrombocy-
topenia. Since the HMW VWF multimers are the most hemo-
statically active, their loss is associated with bleeding risk, as in the
type 2B VWD, which is characterized by a gain of function
abnormality of the VWF molecule caused by several mutations in
the exon 28 of VWF gene located on chromosome 12 [20].
Patients with PT-VWD usually suffer from mild to moderate
mucocutaneous bleeding. Excessive bleeding associatedwith tooth
extractions, tonsillectomies or other surgical procedures is also
possible. The bleeding tendency typically becomes more pro-
nounced following the ingestion of antiplatelet drugs. Laboratory
presentation is characterized by mild thrombocytopenia with
platelet macrocytosis and prolonged bleeding time. Platelet
clumping is observed on blood smears and is caused by the
spontaneous binding of circulating VWF to platelets. Enhanced
platelet aggregation in response to low dose of ristocetin in
ristocetin-induced platelet aggregation (RIPA) assay and loss of
HMW VWF multimers at multimeric analysis are also present.
Plasma VWF testing usually also show a discordance in functional
versus non-functional test parameters (i.e., low ristocetin cofactor
activity [VWF:RCo] and/or collagen binding capacity [VWF:CB]
compared with antigen [VWF:Ag]) [21,22]. Most of the clinical
and laboratory features of PT-VWD are markedly similar to those
of type IIB of VWD. The two conditions can be distinguished by
suitable mixing experiments: addition of plasma from type 2B
VWD patients to normal platelet-rich plasma favours spontaneous
aggregation and ristocetin-induced platelet agglutination, while
plasma from patients with PT-VWD has no effect on normal
platelets. Alternatively, the addition of normal cryoprecipitate
(containing a high concentration of normal VWF) will cause
platelets in platelet-rich plasma from a patient with PT-VWD, but
not type 2B VWD, to aggregate spontaneously (this test is called
also “cryoprecipitate challenge”) [23]. However, since aggrego-
metry results are often ambiguous, the search for mutations in the
GPIBA gene is required to provide diagnostic certainty.
Patients with PT-VWD require platelet transfusions to treat
hemorrhage because of their inherent platelet abnormality and
thrombocytopenia. Increasing thrombocytopenia has been reported
with the use of VWF/FVIII concentrates and cryoprecipitate.
Similarly, desmopressin (DDAVP) is contraindicated in PT-VWD
because the release of large VWF multimers from endothelial
cells could induce in vivo agglutination of platelets and worsen
thrombocytopenia [22]. Recombinant activated factor VII
(rFVIIA) has been successfully used in a case of PT-VWD [24].
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Glanzmann thromboasthenia is a rare autosomal recessive
inherited platelet disorder characterized by impaired platelet
aggregation and due to a defect in the platelet GPIIb–IIIa [22].
The gene encoding for GPIIb and GPIIIa, termed ITGA2B and
ITGB3 respectively is located on chromosome 17. More than
100 different mutations have been described so far, including point
mutations, insertions and deletions [25]. Glanzmann throm-
boasthenia is characterized by a normal platelet count and
morphology, a prolonged bleeding time and defective platelet
aggregation. Testing with platelet function analyzer (PFA-100,
Dade/Behring, Marburg, Germany) shows prolonged closure
times. Thromboasthenic platelets do not aggregate in response to
agonists, such as ADP, collagen, thrombin and adrenaline, but do
agglutinate in the presence of ristocetin. Definitive diagnosis is
made by flow cytometry using antibodies to GPIIb (CD41) and
GPIIIa (CD61).
Bleeding manifestations, usually appearing in early childhood,
range from easy bruising, purpura, epistaxis, gingival bleed,
hematuria, hemarthrosis, muscle hematoma and central nervous
system bleed. When bleeding does not respond to local measures
and/or antifibrinolytic drugs, platelet transfusion is currently the
standard treatment. However, repeated platelet transfusions may
result in GPIIb–IIIa and/or human leukocyte antigen (HLA)
immunization, and development of platelet refractoriness [25].
Thus, in order to avoid sensitization, it should be useful to HLA-
type these patients at diagnosis and, where possible, to transfuse
HLA-selected platelets. Tengborn and Petruson [26] first reported
the successful use of rFVIIa in the management of intractable
epistaxis in a two year old child with GT. On behalf the
International Data Collection on rFVIIa and Congenital Platelet
Disorders Study Group, Poon et al. [27] analyzed the use of rFVIIa
during 34 surgical/invasive procedures and 108 bleeding episodes
in 59GTpatients, including 29with platelet antibodies. rFVIIawas
effective in stopping bleeding in 29 of 31 (94%) evaluable
procedures and in 77 of 103 (75%) evaluable bleeding episodes.
Based on the evidence from the literature, rFVIIa is currently
approved in Europe for prophylaxis and treatment of bleeding in
GT patients with antibodies to GPIIb–IIIa and/or HLA, and past or
present refractoriness to platelet transfusion. The recommended
dose is a bolus injection of 90 μg/kg at 2 hour intervals for a
minimum of 3 doses.
3.3. Bernard-Soulier syndrome
Bernard-Soulier syndrome is an autosomal recessive disorder
characterized by thrombocytopenia with giant platelets. The
underlying defect is the absence or decreased expression on the
surface of the platelets of the GPIb/IX/V complex, which consists
of four subunits (GPIbα, GPIbβ, GPIX, GPV) belonging to the
leucine-rich repeat (LRR) family of proteins. This complex is the
receptor for VWF (see also PT-VWD), so that defects result in
deficient binding of VWF to the platelet membrane resulting in
defective platelet adhesion [28]. The four components of the
complex are encoded by genes on different chromosomes:
GPIBA on chromosome 17, GPIBB on chromosome 22, GPIXand GPV on chromosome 3. Mutations causing Bernard-Soulier
syndrome have been described for all these except GPV. Lab-
oratory diagnosis includes the detection of a variable thrombo-
cytopenia (usually in the range of 30–150×109/l) with increased
platelet size on peripheral blood smear examination. Bleeding
time and PFA-100 are prolonged, while absent ristocetin-induced
platelet agglutination is not corrected by the addition of normal
plasma orVWF. Platelet aggregation independent of the GPIb/IX/
V-VWF interaction, such as that induced by collagen, ADP or
epinephrine, is usually normal. Flow cytometry determination of
platelet GPIb/IX expression is required to confirm the diagnosis
[29].
Clinically, in homozygous Bernard-Soulier syndrome the
bleeding tendency is usually evident from early childhood, but
the severity of symptomsmay change during puberty and adult life.
Moreover, there is a considerable variability in symptoms among
patients, evenwithin a single family. Epistaxis is the most common
symptom, with ecchymoses, menometrorrhagia, gingival hemor-
rhage, and gastrointestinal bleeding also being common. Most
severe bleeding episodes are associated with surgery, dental
extraction or delivery. Heterozygous patients may show a mild to
moderate bleeding tendency [28]. Bleeding episodes in patients
with Bernard-Soulier syndrome can be controlled by platelet
transfusion. Other treatments include the use of DDAVP and
rFVIIa [30].
3.4. Wiskott-Aldrich syndrome
Wiskott-Aldrich syndrome is an X-linked microthrombocyto-
penia associated with abnormal platelet function, severe immune
dysregulation, characterized by eczema, T-cell deficiency, infec-
tions and lymphoproliferative disorders [31,32]. It is caused by
mutation in the WAS gene. More than 150 different mutations
have been identified in the WAS gene, including missense, non-
sense and frameshift mutations. The WAS gene encodes a 502
amino acid protein that is expressed in all hemopoietic lineages.
The WAS protein is implicated in the reorganization of the actin
cytoskeleton, required for many cellular functions such as shape
change, cell division, endocytic processes, locomotion and
chemotaxis [33,34]. Because the gene is located on chromosome
X, most affected patients are male, whereas female carriers
usually have no clinical signs because of the preferential in-
activation of the WAS chromosome X in the hemotopoietic cells.
The diagnosis is made on the basis of the classical triad of
microthrombocytopenia (between 5 and 50×109/l), eczema and
immunodeficiency. Thrombocytopenia is present at birth and
neonates often present with bruising and purpura and are at
increased risk of intracranial hemorrhage. Eczema develops
during the first year of life and may be of varying severity.
Infections, mostly bacterial, occur early, often in the first 6 months
of life [31]. Bleeding episodes are treated with platelet transfusion
(HLA-selected and irradiated platelet should be used). Splenec-
tomymay result in an increase both in platelet number and size but
is associated with a higher risk of sepsis and thus a risk–benefit
analysis should be accurately evaluated in each patient. Bone
marrow transplantation remains the curative therapy in Wiskott-
Aldrich syndrome.
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4.1. Thromboxane A2 receptor deficiency
Defective thromboxane A2 (TXA2) receptor function is
associated with impaired platelet aggregation to arachidonic acid
and thromboxane analogues and a variable response to other
agonists, sometimes comprising a reduced primary wave and
absent secondary wave. The response to ristocetin is preserved.
TXA2 receptor is present in two isoforms,with Tpα predominating
in platelets. Interestingly, mutated Tpα binds TXA2, but
intracellular signaling fails to occur, including stimulation of
adenylate cyclase. Defects in platelet cyclooxygenase or throm-
boxane synthase are associated with a similar laboratory
phenotype using standard laboratory agonists but may be
distinguished from TXA2 receptor defects by preservation of
platelet aggregation in response to prostaglandin-H2 or the
synthetic thromboxane [35].
4.2. ADP receptor defects
Two platelet receptors (P2Y1, P2Y12) mediate adenosine
diphosphate (ADP) interaction with platelets. P2Y1 receptors
induce phospholipase C activation, intracellular Ca2+ mobilization
and shape change, whereas P2Y12 receptors mediate inhibition of
cAMP formation by adenylyl cyclase. ADP-induced aggregation
requires co-activation of both P2Y1 and P2Y12 receptors. Only five
patients with defects in the P2Y12 receptor (which is the target for
clopidogrel) have been described so far. The patients have absent
or impaired platelet aggregation with ADP, and variable
impairment in aggregation to other agonists [36]. This disorder
shows autosomal recessive inheritance but heterozygous indivi-
duals may have a reduced, rather than absent, secondary ag-
gregation response to ADP [37]. Patients with defects in the P2Y1
ADP receptor have not been reported.
A small number of patients with defects in platelet activation
by collagen, attributed to defects in GPVI or GPIa/IIa, and by
epinephrine, due to a decreased number of α2-adrenergic recep-
tors, have been reported [3,38,39]. Finally, abnormalities in
guanine nucleotide binding regulatory proteins (G proteins con-
sisting of α, β and γ subunits) that link surface receptors and
intracellular enzymes, and enzyme deficiencies (cyclooxygenase,
prostaglandin H synthetase-1, thromboxane synthetase, lipox-
ygenase) have been described [35].
Individuals affected by platelet disorders of agonist receptors
and signal transduction usually show a mild bleeding tendency
and should be managed as for other mild platelet disorders (see
Table 1).
5. Disorders of platelet granules
The term storage pool deficiency is used for congenital
platelet disorders associated with deficiency in platelet secretion
granules, which can alter the content of dense granules (δ-
storage pool disease), alpha-granules (α-storage pool disease or
gray platelet syndrome) or both (αδ-storage pool disease).5.1. δ-storage pool disease
A defect in platelet dense-granule content/release includes
idiopathic dense-granule disorder, Chediak-Higashi syndrome and
Hermasnky-Pudlak syndrome. Wiskott-Aldrich syndrome may
also be associated with δ-storage pool disease (see above).
Idiopathic δ-storage pool disease is characterized by a bleeding
diathesis of variable degree, mildly to moderately prolonged skin
bleeding time, abnormal platelet secretion induced by several
platelet agonists, and impaired platelet aggregation. Typically δ-
storage pool disease platelets have decreased levels of δ-granule
constituents: ATP andADP, serotonin, calcium and pyrophosphate.
This disorder may result in defects of platelet aggregation that
range from an abnormal response to all agonists to more subtle
changes, which may only be seen with low concentrations of
agonists. Characteristic features are the absence of second wave
aggregation to adrenaline, a delayed reduced response to collagen,
impaired aggregation to low concentration of agonists such as
arachidonic acid and a full, irreversible aggregation with high
concentrations of ADP [40].
Chediak-Higashi syndrome is an autosomal recessive disorder
characterized by variable degrees of oculocutaneous albinism and
very large peroxidase-positive cytoplasmic granules in a variety of
hemopoietic (neutrophils) and non-hemopoietic cells. There is a
normal platelet count with a prolonged bleeding time, decreased
dense-granules and abnormal platelet aggregation associatedwith a
bleeding tendency. This syndrome is also characterized by re-
current infections associated with neutropenia, impaired chemo-
taxis, bactericidal activity and abnormal NK function. Chediak-
Higashi syndrome is caused by a series of frameshift and nonsense
mutations in the lysosomal trafficking regulator (LYST) gene
located on chromosome 1 [41]. The only curative therapy for this
otherwise lethal syndrome is bone marrow transplantation [42].
Hermasnky-Pudlak syndrome is an autosomal recessive disease
of subcellular organelles of many tissues, involving abnormalities
of melanosomes, platelet δ-granules and lysosomes. It is charac-
terized by oculocutaneous albinism, a mild bleeding diathesis due
to δ-storage pool disease and ceroid-lipofuscin-like lysosomal
storage disease. To date, Hermansky-Pudlak disease has been
associated with mutation in eight human genes (see Table 1) [43].
5.2. α-storage pool disease
The α granules contain adhesive proteins such as fibrinogen
fibronectin, VWF, thrombospondin and vitronectin. They also
contain growth-promoting factors such as platelet-derived growth
factor, platelet factor IV and transforming growth factor.
Coagulation factors including factor V, high molecular weight
kininogen, factor XI and plasminogen activator inhibitor-1 are also
present.
The α-storage pool disease include the Gray platelet syndrome
the Paris-Trousseau/Jacobsen syndrome, and Quebec syndrome.
Gray platelet syndrome is characterized by platelets that are
large and are devoid of normal α-granule content [44]. This defect
derives from the inability of megakaryocytes to pack secretory
proteins into developing α-granules. Thus, the molecules are
released in the extracellular space of bone marrow, where they are
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dominant and recessive patterns of inheritance have been reported
raising the possibility that the syndrome may be caused by defects
in more than one gene. Laboratory diagnostic features include
thrombocytopenia, which can be as low as 50×109/l, with large
platelets that typically appear gray in Wright-stained peripheral
blood smears due to the reduced or absent content of α-granules.
Several abnormalities of in vitro platelet aggregation have been
described, including an impaired response to thrombin and
collagen [45]. Patients with Gray platelet syndrome have usually
a mild bleeding tendency.
Paris-Trousseau/Jacobsen syndrome is an autosomal dominant
disorder characterized by thrombocytopenia, normal platelet life
span and an increased number of megakaryocytes in the bone
marrow, some of which present signs of abnormal maturation. A
fraction of circulating platelets have giant α-granules. It is usually
associated with other congenital abnormalities, including mental
retardation and facial and cardiac abnormalities. It is due to
heterozygous deletions on the distal part of chromosome 11 that
include the FLI1 gene. The bleeding diathesis is usually mild [46].
Quebec syndrome is an autosomal dominant platelet disorder
which is associated with moderate to severe bleeding pattern and is
characterized by low level of factor V within platelet α-granules.
The defect in factor V is caused by over expression of urokinase-
type plasminogen activator leading to activation of plasmin. The
protease cleaves multimerin, a large protein present in α-granules
which stabilizes factor V. However, many other α-granule proteins
are degradated by the protease, although the α-granule ultrastruc-
ture is preserved. As a consequence, the Quebec platelet disorder is
associated with an absent aggregation response to low-dose
epinephrine, and normal to reduced aggregation with ADP and
collagen. Platelet count is normal to reduced. The abnormal
activation of fibrinolytic cascade explains why bleeding episodes
respond well to antifibrinolytic agents [45,47].
6. Other platelet disorders
6.1. Scott syndrome
Scott syndrome is an autosomal recessive disorder of calcium-
induced phospholipid scrambling and generation of thrombin on
platelets. Thus, activated Scott platelets fail to expose phosphati-
dylserine on their surface with the result that factors Va and Xa fail
to bind, leading to the incapacity of the activated cell surface to
transform prothrombin in thrombin [48]. This lack of thrombin
generation induces a moderate to severe bleeding tendency. Re-
cently a missense mutation in the gene that encodes the lipid
transporter ABCA1 has been found in a patient with Scott
syndrome [49]. The diagnosis of Scott syndrome is confirmed by
flow cytometry. Its treatment includes antifibrinolytic agents and
platelet transfusion.
7. Conclusions
The recent progress in understanding the platelet physiology has
led to the identification of a large number of inherited platelet
disorders. However, their diagnosis is difficult and it often requiresdiagnostic tests available only at specialized coagulation laboratory
centers. Therefore, the correct management of such patients is
possible only through a close cooperation between laboratory and
clinical doctors.
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